Peptic ulcer disease: changes it has undergone over the past 50 years
https://doi.org/10.30629/0023-2149-2020-98-8-583-587
Abstract
This review considers the main changes in our understanding of the etiology of peptic ulcer disease (PUD), its treatment and prevention. It is emphasized that the discovery of H. pylori infection and the implementation of eradication therapy did not solve all the issues related to PUD. Further investigation is needed to study the pathogenesis of idiopathic gastroduodenal ulcers, as well as ulcerative lesions of the stomach and duodenum, caused by various medications (non-steroidal anti-inflammatory drugs in particular).
About the Authors
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation
Russian Federation
Arkadiy A.Sheptulin — MD, PhD, DSc, prof. Dpt. of Propedeutics of Internal Disease, Gastroenterology and Hepatology
11999, Moscow
S. S. Kardasheva
I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation
11999, Moscow
Russian Federation
11999, Moscow
A. A. Kurbatova
I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation
11999, Moscow
Russian Federation
11999, Moscow
References
1. Василенко В.Х. Чего мы не знаем о язвенной болезни. В кн.: Актуальные вопросы гастроэнтерологии. М. 1970;3:3–17. [Vasilenko V.Ch. What we don’t know about peptic ulcer disease. In: Actual questions of gastroenterology. Moscow. 2070;3:3–17. (in Russian)]
2. Shay H., Sun D.C.H. Etiology and pathology of gastric and duodenal ulcer. In: Bockus H.L. Gastroenterology, Philadelphia-London: Saunders Elsevier, 1968:420–65.
3. Василенко В.Х., Гребенев А.Л., Шептулин А.А. Язвенная болезнь. М.: Медицина, 1987. [Vasilenko V.Ch., Grebenev A.L., Sheptulin A.A. Peptic ulcer disease. M, Meditsina, 1987. (in Russian.)]
4. Burget D.W., Chiverton K.D., Hunt R.H. Is there an optimal degree of acid supression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345–51.
5. Warren J.R., Marshall B.J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1983;1:1311– 15.
6. Lanas A., Chan F.K.L. Peptic ulcer disease. Lancet. 2017;390(10094):613–24.
7. Soll A.Y. Peptic ulcer and its complication. In: Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. Philadelphia-LondonToronto-Montreal-Sydney-Tokyo. 1998;1:620–78.
8. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
9. Lau J.Y., Sung J., Hill C. et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84:102–13.
10. Nervi G., Liatopoulou S., Cavallaro L.G. et al. Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A10 years endoscopical survey. World J. Gastroenterol. 2006;12:2398–2401.
11. Bartholomeeusen S., Vandenbroucke J, Truyers C., Buntinx F. Time trends in the incidence of peptic ulcers and oesophagitis between 1994 and 2003. Br. J. Gen .Pract. 2007;57:497–9.
12. Заболеваемость всего населения России в 2006 г. Статистические материалы Минздрава России. М., 2007:98. [Incidence of the entire population of Russia in 2006 years. Statistical materials of the Ministry of health of Russia. Moscow, 2006:98. (in Russian)]
13. Заболеваемость всего населения России в 2018 г. Статистические материалы Минздрава России. М., 2018:101. [Incidence of the entire population of Russia in 2018 years. Statistical materials of the Ministry of health of Russia. Moscow, 2018:101. (in Russian)]
14. Groenen J.M., Kuipers E.J., Hansen B.E. Incidence of duodenal ulcers and gastric ulcers in a Western population: Back to where it started. Can. J. Gastroenterol. 2009;23:604–8.
15. Jang H.J., Choi M.H., Shin W.G. et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multicenter study. Dig. Dis. Sci. 2008;53:1527–31.
16. Carli D.M., Pires R.C., Rohde S.L. Peptic ulcer frequency difference related to H. pylori or aines. Arq. Gastroenterol. 2015;52:46–9.
17. Пятенко Е.А., Шептулин А.А. Язвенная болезнь: изменила ли она свое «лицо»? Росcийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):14–9. [Pyatenko Ye.A., Sheptulin A.A. Peptic ulcer: does it changed its identity. Russian Journal of Gastroenterologii, Hepatologii, Coloproctologii. 2017;27(6):14–19. (in Russian)]
18. Eusebi L., Zagari M., Bazolli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19(1):1–5.
19. Chung C.-S., Chiang T.-H., Lee Y.-C. A systemiс approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J. Intern. Med. 2015;30(5):559–570.
20. Jyotheeswaran S., Shah A.N., Jin H.O. et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? A. J. Gastroenterol. 1998;93:574–578.
21. Charpignon C., Lesgourgues B., Pariente A. et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Alimrnt. Pharmacol. Ther. 2013;38:946–954.
22. Gispert L.P., Calvet X. Helicobacter pylori-negative duodenal ulcer disease. Aliment. Pharmacol. Ther. 2009;30:791–815.
23. Kanno T., Iijima K., Abe Y. et al. A multicenter prospective study on the prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drugs-negative idiopathic peptic ulcers in Japan. J. Gastroenterol. Hepatol. 2015;30:842–848.
24. Хакимова Д.Р., Шептулин А.А., Ивашкин В.Т. Особенности часторецидивирующей язвенной болезни двенадцатиперстной кишки. Тезисы Девятой Российской гастроэнтерологической недели. Росcийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2003;13(2):55. [Chakimova D.R., Sheptulin A.A., Ivashkin V.T. Features of frequently recurring duodenal ulcer disease. Abstracts of the 9th Russian Gastroenterological Week. Russian Journal of Gastroenterologii, Hepatologii, Coloproctologii. 2003;13(2):55. (in Russian)]
25. Arroyo M.T., Fome M., de Argila V.M. et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal antiinflammatory drug use is negligible in southern Europe. Helicobacter. 2004;9(3):249–254.
26. Kiatapapan P., Vilalchone R.K., Chotivitayatarakom P., Mahachai V. Gastric cancer and gastrointestinal stromal tumors could be causes of non-Нelicobacter pylori non-NSAID peptic ulcers in Thailand. Asian Pac. J. Cancer Prev. 2017;18(1):155–157.
27. Kanno T., Iijima K., Abe Y. Peptic ulcers after the Great East Japan Earthquаke and Tsunami: possible existence of psychosocial stress ulcers in humans. J. Gastroenterol. 2013;48:483–490.
28. Niv Y., Boltin D., Halpem M. et al. Membrane-bound mucins and mucin terminal glycans in idiopathic or Helicobacter pylori, NSAID associated peptic ulcers. World J. Gastroenterol. 2014;20(40):14013– 14920.
29. Straube S., Tramer M.R., Moore R.A. et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41.
30. Deepak L.B., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAIDs use. Circulation. 2008;118:1894–909.
31. Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology. 2010;49(2):3–10.
32. Hawkey C.I., Wight N.J. NSAIDs and gastrointestinal complications. LSC Life Science Communications. London, 2001:1–56.
33. Ивашкин В.Т., Шептулин А.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Росcийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(6):89–94. [Ivashkin V.T., Sheptulin A.A., Maev I.V. et al. Russian gastroenterological association guidelines on diagnostics and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenum. Russian Journal of Gastroenterologii, Hepatologii, Coloproctologii. 2014;24(6):89–94. (in Russian)]
34. Valkhoff V.E., van Soest E.M., Mazzaglia G.M. et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events. Arthritis Rheum. 2012;64(8):2792–2802.
35. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C. et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized trial. Lancet. 2007;369:1621– 1626.
36. Targownik L.E., Metge C.J., Leung S., Chateau D.G. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal antiinflammatory drugs. Gastroenterology. 2008;134(4):937–944.
37. Шептулин А.А., Кардашева С.С., Курбатова А.А. Факторы риска желудочно-кишечных кровотечений, вызванных приемом новых пероральных антикоагулянтов и их профилактика. Клиническая медицина. 2018;96(11):965–9. [Sheptulin A.A., Kardasheva S.S., Kurbatova A.A. Risk factors of gastrointestinal bleeding caused by novel oral anticoagulants and prevention. Klinicheskaya meditsina. 2018;96(11):965–9. (in Russian)]
38. Циммерман Я.С. Нерешенные и спорные проблемы современной гастроэнтерологии. М., МЕДпресс-информ», 2013. [Tsimmerman J.S. Unsolved and debatable issues of modern gastroenterology. W., MEDpress-inform, 2013. (in Russian)]
Review
For citations:
Sheptulin A.A., Kardasheva S.S., Kurbatova A.A. Peptic ulcer disease: changes it has undergone over the past 50 years. Clinical Medicine (Russian Journal). 2020;98(8):583-587. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-8-583-587
Views:
817
Email this article 